DS-9606 Shows Promising Preliminary Clinical Activity in Patients with Advanced Solid Tumors

Initial results from Daiichi Sankyo’s phase 1 trial of DS-9606, a CLDN6-directed ADC, show promising clinical activity in advanced solid tumors expressing CLDN6, with no dose-limiting toxicities observed.